Please assess the completion status of the following clinical trial:

Trial Title: Carvedilol PAH A Pilot Study of Efficacy and Safety

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects will be eligible to participate in the study if all of the following conditions exist:~2. Age \> 18 years~3. WHO category 1 pulmonary arterial hypertension (Dana Point 2008)~4. WHO functional class II-III~5. RVEF by cardiac MRI \< 40%~6. Mean pulmonary artery pressure \> 40 mm Hg~7. Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months. Patient can be on either mono or combination PAH-specific therapy~Exclusion Criteria:~* 1. Subjects will be excluded from participation in the study if any of the following conditions exist: 2. Significant persistent bradycardia (resting heart rate \< 60 bpm) without a permanent pacemaker 3. Second or third degree AV block without a permanent pacemaker 4. Significant sinus tachycardia (resting heart rate \> 100 bpm) 5. Use of anti-arrhythmic drugs 6. Hypotension defined as systolic blood pressure \< 100 mmHg at the time of enrollment 7. Significant illness in the past 30 days requiring hospitalization 8. Acute decompensated right heart failure within past 30 days 9. Known allergy or intolerance to carvedilol or other β blockers 10. Cardiac index \< 2 l/min/m2 or right atrial pressure \> 15 mm Hg 11. Asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).